£5 allows us to reach millions of people globally with accurate and reliable resources about HIV prevention and treatment. £10 helps us produce news and bulletins on the latest developments in HIV for ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Advances in care over the last 30 years have helped transform HIV from a fatal disease into a chronic, manageable condition for many people. 1 Innovations in treatment and access are at the core ...